Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | The influence of the pulmonary microbiome on outcomes after alloHSCT

Jaap Jan Boelens • 24 Apr 2022
The 2022 Tandem Meetings
General

Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, gives an overview of the results of a study exploring the impact of the pulmonary microbiome on patient outcomes after allogeneic hematopoietic stem cell transplantation (alloHSCT). The study identified two inflammatory microbial clusters associated with an increased incidence of alloreactive lung diseases. This data could help intervene earlier in patients at a high risk of developing an alloreactive lung syndrome. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Jaap Jan Boelens

Gene therapy as the standard of care for patients with SCD who lack a matched sibling donor
2:05
Gene therapy as the standard of care for patients with SCD who lack a matched sibling donor
Jaap Jan Boelens • 6 Sep 2024
Navigating U.S. healthcare insurance when treating patients with SCD
1:44
Navigating U.S. healthcare insurance when treating patients with SCD
Jaap Jan Boelens • 6 Sep 2024
The need for up-to-date and evidence-based data for the use of DLIs in SCD
2:22
The need for up-to-date and evidence-based data for the use of DLIs in SCD
Jaap Jan Boelens • 6 Sep 2024
The SCD treatment landscape: preventive medicine, disease-modifying agents, and curative approaches
1:21
The SCD treatment landscape: preventive medicine, disease-modifying agents, and curative approaches
Jaap Jan Boelens • 6 Sep 2024

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI for clinical decision-making
2:25
Addressing the risk of over-reliance on AI for clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals